heparin sodium in 5% dextrose injection 50 units/ml and 100 units/ml Adverse Reactions

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

•
Hemorrhage [see Warnings and Precautions (5.2)]
•
Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia with Thrombosis [see Warnings and Precautions (5.3)]
•
Thrombocytopenia [see Warnings and Precautions (5.4)]
•
Heparin Resistance [see Warnings and Precautions (5.6)]
•
Hypersensitivity [see Warnings and Precautions (5.7)]
•
Hyperkalemia [see Warnings and Precautions (5.8)]
•
Elevations of Serum Aminotransferases [see Warnings and Precautions (5.9)]

6.1 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of heparin sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

•
Hemorrhage - Hemorrhage is the chief complication that may result from heparin therapy [see Warnings and Precautions (5.2)]. An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing the drug [see Overdosage (10)]. Gastrointestinal or urinary tract bleeding during anticoagulant therapy may indicate the presence of an underlying occult lesion. Bleeding can occur at any site but certain specific hemorrhagic complications may be difficult to detect:
a.
Adrenal hemorrhage, with resultant acute adrenal insufficiency, has occurred with heparin therapy, including fatal cases.during anticoagulant therapy.
b.
Ovarian (corpus luteum) hemorrhage developed in a number of women of reproductive age receiving short- or long-term anticoagulant therapy.
c.
Retroperitoneal hemorrhage.
•
Vascular Disorders – Contusion, vasospastic reactions (including episodes of painful, ischemic, and cyanosed limbs).
•
HIT and HITT, including delayed onset cases, and Thrombocytopenia - [see Warnings and Precautions (5.3, 5.4)]
•
Histamine-like reactions – Such reactions have been observed at the site of injections. Necrosis of the skin has been reported at the site of subcutaneous injection of heparin, occasionally requiring skin grafting.
•
Hypersensitivity – Generalized hypersensitivity reactions have been reported with chills, fever, and urticaria as the most usual manifestations, and asthma, rhinitis, lacrimation, headache, nausea and vomiting, and anaphylactoid reactions, including shock, occurring more rarely. Itching and burning, especially on the plantar site of the feet, may occur [see Warnings and Precautions (5.7)].
•
Musculoskeletal, Connective Tissue and Bone Disorders – Osteoporosis with long-term administration of heparin.
•
Metabolism and Nutrition Disorders – Hyperkalemia.
•
General Disorders and Administration Site Conditions – Erythema, mild pain, ulceration.
•
Elevations of Serum Aminotransferases – Significant elevations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels have occurred in patients who have received heparin.
•
Others – Osteoporosis following long-term administration of high-doses of heparin, cutaneous necrosis after systemic administration, suppression of aldosterone synthesis, delayed transient alopecia, priapism, and rebound hyperlipemia on discontinuation of heparin sodium have also been reported.

Find heparin sodium in 5% dextrose injection 50 units/ml and 100 units/ml medical information:

Find heparin sodium in 5% dextrose injection 50 units/ml and 100 units/ml medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

heparin sodium in 5% dextrose injection 50 units/ml and 100 units/ml Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Adverse Reactions

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

•
Hemorrhage [see Warnings and Precautions (5.2)]
•
Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia with Thrombosis [see Warnings and Precautions (5.3)]
•
Thrombocytopenia [see Warnings and Precautions (5.4)]
•
Heparin Resistance [see Warnings and Precautions (5.6)]
•
Hypersensitivity [see Warnings and Precautions (5.7)]
•
Hyperkalemia [see Warnings and Precautions (5.8)]
•
Elevations of Serum Aminotransferases [see Warnings and Precautions (5.9)]

6.1 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of heparin sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

•
Hemorrhage - Hemorrhage is the chief complication that may result from heparin therapy [see Warnings and Precautions (5.2)]. An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing the drug [see Overdosage (10)]. Gastrointestinal or urinary tract bleeding during anticoagulant therapy may indicate the presence of an underlying occult lesion. Bleeding can occur at any site but certain specific hemorrhagic complications may be difficult to detect:
a.
Adrenal hemorrhage, with resultant acute adrenal insufficiency, has occurred with heparin therapy, including fatal cases.during anticoagulant therapy.
b.
Ovarian (corpus luteum) hemorrhage developed in a number of women of reproductive age receiving short- or long-term anticoagulant therapy.
c.
Retroperitoneal hemorrhage.
•
Vascular Disorders – Contusion, vasospastic reactions (including episodes of painful, ischemic, and cyanosed limbs).
•
HIT and HITT, including delayed onset cases, and Thrombocytopenia - [see Warnings and Precautions (5.3, 5.4)]
•
Histamine-like reactions – Such reactions have been observed at the site of injections. Necrosis of the skin has been reported at the site of subcutaneous injection of heparin, occasionally requiring skin grafting.
•
Hypersensitivity – Generalized hypersensitivity reactions have been reported with chills, fever, and urticaria as the most usual manifestations, and asthma, rhinitis, lacrimation, headache, nausea and vomiting, and anaphylactoid reactions, including shock, occurring more rarely. Itching and burning, especially on the plantar site of the feet, may occur [see Warnings and Precautions (5.7)].
•
Musculoskeletal, Connective Tissue and Bone Disorders – Osteoporosis with long-term administration of heparin.
•
Metabolism and Nutrition Disorders – Hyperkalemia.
•
General Disorders and Administration Site Conditions – Erythema, mild pain, ulceration.
•
Elevations of Serum Aminotransferases – Significant elevations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels have occurred in patients who have received heparin.
•
Others – Osteoporosis following long-term administration of high-doses of heparin, cutaneous necrosis after systemic administration, suppression of aldosterone synthesis, delayed transient alopecia, priapism, and rebound hyperlipemia on discontinuation of heparin sodium have also been reported.
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.